Tilak Jani
About Tilak Jani
Tilak Jani is the Myeloid, Lymphoma, and Portfolio Lead for Worldwide Hematology at Bristol Myers Squibb, with extensive experience in pharmaceutical management and strategic planning.
Current Position at Bristol Myers Squibb
Tilak Jani currently serves as the Myeloid, Lymphoma, and Portfolio Lead for Worldwide Hematology, Enterprise Strategy & Performance at Bristol Myers Squibb in Summit, New Jersey. In this role, he oversees the strategic planning and execution for the global myeloid and lymphoma portfolios. His responsibilities include leading enterprise strategy and performance initiatives within the hematology therapeutic area.
Previous Roles at Bristol Myers Squibb
Before his current position, Tilak Jani worked as the Portfolio, Early Assets & Lymphoma Lead for Worldwide Hematology at Bristol Myers Squibb from 2020 to 2021. He was tasked with early and late-stage asset management within hematology. Prior to that, he held the position of Senior Manager, Enterprise Strategy Analytics, Worldwide Oncology, from 2019 to 2020, where he contributed to analytics-driven strategies.
Experience at Decision Resources Group
Tilak Jani worked at Decision Resources Group from 2015 to 2019. He started as a Senior Consultant and later became the Client Engagement Lead for Analytics. During his time there, he focused on client engagement and analytics, helping organizations develop data-informed strategies.
Educational Background
Tilak Jani earned an MBA in Marketing and Pharmaceutical Management from Rutgers, The State University of New Jersey-Newark, from 2009 to 2012. He also holds a Master's in Biotechnology from the University of Pennsylvania, which he obtained from 2007 to 2008. Additionally, he completed a Bachelor of Science (B.S.) in Biomedical Engineering from Rutgers, The State University of New Jersey-New Brunswick.
Early Career and Diverse Professional Background
Tilak Jani has a diverse professional background, having worked in various roles across multiple industries. He has experience in manufacturing and validation from his early career at Alexion Pharmaceuticals and DPT Laboratories. Later, he gained marketing and management experience at Novo Nordisk A/S and Forest Laboratories. This diverse skill set complements his strategic roles in pharmaceutical management.